72
Participants
Start Date
February 12, 2019
Primary Completion Date
December 31, 2022
Study Completion Date
July 31, 2023
P1101 (Ropeginterferon alfa-2b)
solution for injection in prefilled syringe, 500 µg/ mL , 450μg /time, subcutaneous injection every 2 weeks
Nivolumab
"Phase I study will use 0.3, 0.75, 1.5, 3mg/kg, Q2W for 3 doses after 6 doses of P1101.~Phase II study : Group I will use 3mg/kg, Q2W for 3 doses; Group III will use the dosage that determine from Phase I study 3 doses after 6 doses of P1101"
RECRUITING
National Taiwan university Hospital, Taipei
Collaborators (1)
PharmaEssentia
INDUSTRY
National Taiwan University Hospital
OTHER